Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.51 |
| ▸ | CPS1 | P31327 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30514003 | 0.87 | CPS1 (0.55) | CLK1DYRK1ADYRK1BCPS1MAPT | |
| SCHEMBL12345357 | 0.85 | CA12 (0.42) | CLK1DYRK1ADYRK1BMAPTSMN1; SMN2 | |
| SCHEMBL28411038 | 0.85 | KAT6A (0.47) | CPS1MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4007735 | 0.83 | CES2 (0.53) | CLK1DYRK1ADYRK1BMAPTHTT | |
| SCHEMBL4093630 | 0.82 | CLK1 (0.52) | CLK1DYRK1ADYRK1BMAPTHTT | |
| SCHEMBL4833864 | 0.82 | MAPT (0.58) | CLK1DYRK1ADYRK1BMAPTHTT | |
| SCHEMBL29554674 | 0.82 | PKM (0.45) | HTTRAB9A | |
| SCHEMBL12093236 | 0.82 | MLYCD (0.39) | CLK1DYRK1ADYRK1BCPS1MAPT | |
| SCHEMBL19285067 | 0.82 | PKM (0.45) | HTTRAB9A | |
| SCHEMBL20812224 | 0.81 | CPS1 (0.42) | CPS1MAPTHTTNPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | HDAC10, HDAC11, HDAC1 | CLK1 4724/4885DYRK1A 3927/4885DYRK1B 4150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.